Table 1.
Baseline characteristics, drug treatment and neurohormonal data stratified by UCP2 genotype group.
| UCP2 Genotype | |||||||
| n | AA | n | GA | n | GG | p | |
| Gender (M/F) | 140 | 102/38(72.9%M) | 410 | 309/101(75.4%M) | 351 | 292/59 (83.2%M) | 0.009 |
| Age (years)* | 140 | 61.5 ± 0.94 | 410 | 62.0 ± 0.49 | 350 | 62.7 ± 057 | 0.404 |
| BMI* (kgm-2) | 92 | 27.2 ± 0.51 | 285 | 26.9 ± 0.25 | 239 | 26.4 ± 0.25 | 0.174 |
| LVEF | 113 | 47.2 ± 1.00 | 348 | 48.0 ± 0.64 | 288 | 47.9 ± 0.72 | 0.822 |
| Predischarge Mean arterial pressure (mmHg) | 133 | 82.9 ± 0.87 | 397 | 83.2 ± 0.55 | 341 | 84.6 ± 0.61 | 0.145 |
| Predischarge Systolic Blood pressure (mmHg) | 133 | 117 ± 1.28 | 397 | 116 ± 0.81 | 341 | 118 ± 0.90 | 0.163 |
| Predischarge Diastolic Blood pressure (mmHg)(mmHg) | 133 | 65.9 ± 0.82 | 397 | 66.8 ± 0.54 | 341 | 67.8 ± 0.57 | 0.176 |
| History | |||||||
| Previous myocardial infarction* | 127 | 24(18.9%) | 389 | 72 (18.5%) | 334 | 58 (17.4%) | 0.896 |
| hypertension * | 129 | 47(36.4%) | 400 | 157 (39.3%) | 342 | 131 (38.3%) | 0.847 |
| Type 2 Diabetes* | 139 | 22(15.8%) | 409 | 48(11.7%) | 349 | 38 (10.9%) | 0.308 |
| Predischarge Atrial Fibrillation* Fibrillation* |
112 | 12(10.7%) | 346 | 35 (10.1%) | 297 | 47 (15.8%) | 0.076 |
| Predischarge Ventricular Fibrillation* Fibrillation* | 113 | 11(9.7%) | 355 | 40 11.3%) | 300 | 21 (7.0%) | 0.173 |
| Laboratory Data | |||||||
| Total Cholesterol* (mmol/l) | 130 | 5.94 ± 0.10 | 376 | 5.95 ± 0.065 | 330 | 5.81 ± 0.068 | 0.325 |
| HDL Cholesterol* (mmol/l) | 129 | 1.16 ± 0.026 | 371 | 1.16 ± 0.017 | 325 | 1.15 ± 0.018 | 0.913 |
| LDL Cholesterol* (mmol/l) | 97 | 3.96 ± 0.10 | 299 | 3.98 ± 0.058 | 268 | 3.83 ± 0.069 | 0.225 |
| Triglycerides* (mmol/l) | 130 | 2.02 ± 0.11 | 376 | 2.08 ± 0.096 | 330 | 2.01 ± 0.069 | 0.791 |
| Plasma Creatinine† (μmol/l) | 136 | 83 (79–87) | 405 | 85 (82–87) | 347 | 85 (83–87) | 0.600 |
| Creatinine Clearance* (ml/s) | 99 | 1.28 ± 0.047 | 308 | 1.28 ± 0.023 | 267 | 1.32 ± 0.028 | 0.546 |
| Peak Creatine kinase† (units/l) | 105 | 1440(1250–1660) | 327 | 1610(1480–1740) | 269 | 1640(1510–1680) | 0.304 |
| Plasma Glucose (mmol/l) | 137 | 8.55 ± 0.27 | 404 | 8.64 ± 0.15 | 344 | 8.55 ± 0.16 | 0.912 |
| Glycated Hemoglobin % | 105 | 6.07 ± 0.11 | 324 | 6.06 ± 0.06 | 274 | 6.03 ± 0.06 | 0.905 |
| Discharge Medications | |||||||
| ACE inhibitor * | 122 | 36(29.5%) | 374 | 121 (32.4%) | 318 | 109 (34.3%) | 0.624 |
| β-blocker * | 122 | 78(63.9%) | 374 | 232 (62.0%) | 318 | 176 (55.3%) | 0.119 |
| Neurohormonal Data | |||||||
| ANP (pmol/l)‡ | 138 | 26.8(24.4–29.4) | 403 | 28.5(27.0–30.0) | 346 | 28.8(27.1–30.6) | 0.406 |
| BNP (pmol/l)‡ | 138 | 18.2(16.4–20.2) | 404 | 19.8(18.7–21.0) | 346 | 19.9(18.8–21.1) | 0.290 |
| NTproBNP (pmol/l)‡ | 137 | 98.6(87.0–112) | 399 | 112(104–121) | 344 | 111(103–121) | 0.200 |
| Endothelin-1 (pmol/l)‡ | 137 | 1.64(1.52–1.77) | 398 | 1.80(1.73–1.88) | 340 | 1.76(1.167–1.81) | 0.110 |
*Means (SEM) or occurrence (percentage); †Median (range); ‡Geometric mean (95% confidence interval).